M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial
R.A.P. Weir,R.A.P. Weir,John J.V. McMurray,John J.V. McMurray,Margareta Puu,Scott D. Solomon,Bertil Olofsson,Christopher B. Granger,Salim Yusuf,Eric L. Michelson,Karl Swedberg,Marc A. Pfeffer,Charm Investigators +12 more
TL;DR: The CHARM-Added trial described the largest experience of using multiple inhibitors of the renin-angiotensin-aldosterone system (RAAS) together as discussed by the authors, and showed that ARB may provide added benefit, at acceptable risk, in heart failure patients already taking spironolactone as well as an ACE-I and a beta blocker.
Book ChapterDOI
Tick-Borne Encephalitis: From Microfocus to Human Disease
TL;DR: The results of longitudinal studies showed that the areas, where positive ticks could be repeatedly detected, were relatively small in comparison to earlier descriptions, implying that the natural circulation of TBEV between ticks and rodents or other small mammals occurs in rather small areas, named microfoci.
Journal ArticleDOI
The Future of Clinical Trials in Cardiovascular Medicine.
Scott D. Solomon,Marc A. Pfeffer +1 more
TL;DR: Despite the success of clinical trials in cardiovascular medicine over the past 25 years, the ability to bring new cardiovascular therapies to patients will require new approaches to curtail cost and maintain quality of future trials.
Journal ArticleDOI
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Marwa A. Sabe,Brian Claggett,Emmanuel A. Burdmann,Akshay S. Desai,Peter Ivanovich,Reshma Kewalramani,Eldrin F. Lewis,John J.V. McMurray,Kurt Olson,Patrick S. Parfrey,Scott D. Solomon,Marc A. Pfeffer +11 more
TL;DR: In patients with chronic kidney disease, diabetes, and anemia, a history of CAD is an independent predictor of progression to dialysis and contributes important prognostic information to traditional risk factors for worsening renal disease.
Journal ArticleDOI
Ejection fraction by radionuclide ventriculography and contrast left ventriculogram: A tale of two techniques
Pedro E. Urena,Gervasio A. Lamas,Gary F. Mitchell,Greg C. Flaker,Sidney C. Smith,Frans J. Th. Wackers,Patricia McEwan,Marc A. Pfeffer +7 more
TL;DR: In this paper, the authors compared the abilities of two methods to measure ejection fraction (EF) and contrast left ventriculography (CFA) to predict cardiovascular events.